New research indicates that patients taking Wegovy, the higher-dose semaglutide medication for weight loss, face an almost five times greater risk of sudden, irreversible vision loss compared to those using Ozempic, a lower-dose drug primarily prescribed for type 2 diabetes. The findings, based on analysis of seven years of adverse event reports submitted to the US Food and Drug Administration (FDA), raise concerns about formulation-specific risks associated with GLP-1 medications.
GLP-1 Drugs and Vision Loss: A Growing Concern
GLP-1 drugs, including Wegovy, Ozempic, and Rybelsus, work by mimicking a natural hormone to suppress appetite and regulate blood sugar. While widely used for weight management and diabetes treatment, reports of eyesight problems linked to semaglutide – the active ingredient in these medications – have surged. This has prompted regulators in the UK and Europe to initiate safety reviews. The latest study aimed to quantify the relationship between semaglutide formulations and ischemic optic neuropathy (ION), a rare but severe condition causing sudden vision loss due to restricted blood flow to the optic nerve.
Study Details and Findings
Researchers from Canadian universities analyzed over 30 million adverse event reports filed with the FDA between 2017 and 2024. The analysis revealed a stark difference in ION risk. Wegovy was associated with 28 reported cases, while Ozempic had 47 cases. Despite Ozempic being prescribed for a longer period, statistical analysis showed that the odds of ION were 4.74 times higher among Wegovy users than Ozempic users, even after accounting for age and gender. Notably, no significant link was found between Rybelsus and ION.
Gender and Dosage: Key Factors
The study also identified a gender disparity: men taking any semaglutide medication were approximately three times more likely to report ION than women. The researchers hypothesize that Wegovy’s higher dosage may contribute to lower blood pressure, potentially reducing blood supply to the optic nerve, though further investigation is needed.
Why This Matters
This research adds to a growing body of evidence detailing the complex side effects of GLP-1 medications. The FDA database analyzed contains millions of reports; the observed numbers of ION cases, while small in proportion, are statistically significant given the drug formulations. The findings underscore the need for careful monitoring and further prospective studies.
The increasing use of GLP-1 drugs for weight loss, coupled with potential safety risks, highlights the tension between addressing urgent public health concerns (like obesity) and ensuring patient safety. Experts emphasize that while these findings are associations from a single database, they warrant immediate investigation to refine prescribing guidelines and regulatory policies.
The study demonstrates a clear dose-dependent safety concern that calls for urgent evaluation to guide prescribing and regulatory policy.
The complex picture emerging around GLP-1 drugs extends beyond vision loss, with prior research linking them to reduced cancer risk, depression, and even bone/joint problems. Ongoing research is critical to fully understand the long-term consequences of these medications.
